Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).
Ricardo Spielberger , Christos Emmanouilides , William Bensinger , Alan Rong
Blood 106 ( 11) 2925 -2925
1
2005
O-0014 Effect of Post-Protocol anti-EGFR mAb Therapy on Survival Outcomes in Patients with Wild-Type Kras MCRC Treated with Panitumumab Plus Chemotherapy
Jean-Yves Douillard , Marc Peeters , Alan Rong , Salvatore Siena
Annals of Oncology 23
2012
PD-0019 Benefit of Panitumumab (pmab) as Monotherapy in Patients with WT KRAS mCRC: A Number-Needed-To-Treat (NNT) Analysis
Eric Van Cutsem , Alan Rong , Yves Humblet , Salvatore Siena
Annals of Oncology 23 25 -25
2012
PD-0023 Benefit of Adding Panitumumab (pmab) To 1St/2Nd-Line Chemotherapy in Patients with KRAS WT mCRC: A Number-Needed-To-Treat (NNT) Analysis
Michel Ducreux , Marc Peeters , Salvatore Siena , Jean-Yves Douillard
Annals of Oncology 23
2012
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters , Timothy Jay Price , Andrés Cervantes , Alberto F. Sobrero
Journal of Clinical Oncology 28 ( 31) 4706 -4713
1,165
2010
Pattern mixture models for clinical validation of biomarkers in the presence of missing data.
Fei Gao , Jun Dong , Donglin Zeng , Alan Rong
Statistics in Medicine 36 ( 19) 2994 -3004
2017
Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy.
Tu Xu , Yixin Fang , Alan Rong , Junhui Wang
BMC Medical Research Methodology 15 ( 1) 94 -94
17
2015
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
Kelly S Oliner , Jean-Yves Douillard , Salvatore Siena , Josep Tabernero
Journal of Clinical Oncology 31 3511 -3511
49
2013
Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.
Guoqing Diao , Donglin Zeng , Joseph G. Ibrahim , Alan Rong
Journal of Biopharmaceutical Statistics 27 ( 6) 933 -944
3
2017
Biomarker threshold adaptive designs for survival endpoints.
Guoqing Diao , Jun Dong , Donglin Zeng , Chunlei Ke
Journal of Biopharmaceutical Statistics 28 ( 6) 1038 -1054
4
2018
Estimation of delay time in survival data with delayed treatment effect.
Wei Li , Sophie Yu-Pu Chen , Alan Rong
Journal of Biopharmaceutical Statistics 29 ( 2) 229 -243
5
2019
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
J. Randolph Hecht , Jean-Yves Douillard , Lee Schwartzberg , Axel Grothey
Cancer Treatment Reviews 41 ( 8) 653 -659
36
2015
Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Roger Sidhu , Alan Rong , Steve Dahlberg
Clinical Cancer Research 19 ( 5) 969 -976
43
2013
Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect
Chenghao Chu , Shufang Liu , Alan Rong
Pharmaceutical Statistics 19 ( 4) 358 -369
1
2020
Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Shufang Liu , Chenghao Chu , Alan Rong
Pharmaceutical Statistics 17 ( 5) 541 -554
8
2018
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard , Kelly S Oliner , Salvatore Siena , Josep Tabernero
The New England Journal of Medicine 369 ( 11) 1023 -1034
1,502
2013
The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone.
Jianmin Wang , Jun Dong , Guy Hechmati , Alan Rong
Journal of Clinical Oncology 33 ( 15_suppl) 3543 -3543
1
2015
Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in the PRIME trial.
Jianmin Wang , Jun Dong , Patrick Johnson , Gregory A Maglinte
Journal of Clinical Oncology 33 537 -537
1
2015
Evaluation of KRAS, NRAS, and BRAF mutations in PRIME: panitumumab with FOLFOX4 as first-line treatment in metastatic colorectal cancer (mCRC)
Kelly Oliner , Jean-Yves Douillard , Salvatore Siena , Josep Tabernero
Annals of Oncology 24 iv23 -iv24
3
2013
Palifermin treatment of mucositis in transplant patients reduces health resource use: phase 3 results
Christos Emmanouilides , Ricardo Spielberger , Patrick Stiff , Alan Rong
Blood 102 ( 11) 251a -251a
29
2003